Research programme: antibacterials - Microbiotix/Millenia Hope BiopharmaAlternative Names: Antibacterials research programme - antibacterials - Microbiotix/Avance Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator Microbiotix; Millenia Hope Biopharma
- Class Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 21 Feb 2006 Avance Pharma has been acquired and merged into Millenia Hope Biopharma